Related keylists
SymBio Pharmaceuticals Ltd (SymBio) is a biopharmaceutical company that develops and markets anti-cancer drug candidates. The company's pipeline product portfolio includes Treakisym (SyB L-0501), an anti-cancer agent used for the treatment of non-Hodgkin's lymphoma (NHL), multiple myeloma (MM) and chronic lymphocytic leukemia (CLL), rigosertib (SyB L-1101), a novel tumor-specific kinase inhibitor targeting hematologic malignancies and solid tumors and Brincidofovir (SyB V-1901) for effective treatment against a wide spectrum of infectious diseases caused by DNA viruses, including herpes viruses (including CMV), adenovirus, BK virus, papillomavirus and smallpox virus. It offers business and product development services in the areas of oncology, hematology and pain-management areas. SymBio is headquartered in Minato-ku, Tokyo, Japan.
Headquarters
Japan
Address
Toranomon 30 Mori Bldg., 3-2-2, Toranomon, Minato-Ku, Tokyo, 105-0001
Website
www.symbiopharma.com
Telephone
81 3 54721125
No of Employees
118
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4582 (TYO)
Revenue (2022)
$41.3M
-44.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-266.4%
(2022 vs 2021)
Market Cap*
$52.4M
Net Profit Margin (2022)
XYZ
-398.1%
(2022 vs 2021)
* As of and is in US$
SymBio Pharmaceuticals Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Treakisym |
| Treakisym (SyB L-0501): | |
| SyB L-1701: | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In April, the company entered into a cooperative research and development agreement with the National Institute of Allergy and Infectious Diseases to investigate the efficacy of brincidofovir in the treatment of Epstein-Barr virus diseases. |
| 2022 | Contracts/Agreements | In December, the company entered into a sponsored research agreement with Tufts University to conduct joint research on the intravenous formulation of the anti-viral drug brincidofovir. |
| 2022 | Contracts/Agreements | In November, the company entered into an agreement with Penn State College of Medicine to provide intravenous formulation of the anti-viral drug brincidofovir for use in a non-clinical study. |
Competitor Comparison
| Key Parameters | SymBio Pharmaceuticals Ltd | Torii Pharmaceutical Co Ltd | Fuso Pharmaceutical Industries Ltd | Daito Pharmaceutical Co Ltd | Fuji Pharma Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Minato-Ku | Chuo-Ku | Osaka-Shi | Toyama-Shi | Chiyoda-Ku |
| State/Province | Tokyo | Tokyo | Osaka | Toyama | Tokyo |
| No. of Employees | 118 | 583 | 1,314 | 1,011 | 1,621 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Fuminori Yoshida | Director; President; Corporate Officer; Chief Executive Officer | Executive Board | - | - |
| Takaaki Fukushima | Executive Corporate Officer; Chief Financial Officer | Senior Management | - | - |
| Yoshiharu Torikai | Corporate Officer | Senior Management | - | - |
| Koji Fukushima | Corporate Officer; Chief Medical Officer - Deputy; Medical Lead, Transplantation Area | Senior Management | - | - |
| Masahiko Okuno | Corporate Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward